成人脑积水的临床谱系:AHCRN注册研究首批517例报告
该研究描述了成人脑积水临床研究网络(AHCRN)前2年入组的517例成人患者的 demographics 和临床特征。患者分为过渡期、未识别先天性、获得性和疑似iNPH四类,比例分别为16.6%、26.5%、18.2%和38.7%。仅39%为疑似iNPH,43%为儿童期起病;症状严重程度与病因导致的神经损伤及合并症数量相关。
要点
- 成人脑积水谱系远不止iNPH或获得性脑积水,43%为儿童期起病。
- 排除过渡期组后,近80%患者在入组时未接受治疗。
- 疑似iNPH患者认知和步态表现最差,未识别先天性患者表现最佳。
核心结论
- 成人脑积水临床谱系包括过渡期、未识别先天性、获得性和疑似iNPH四类,仅39%为疑似iNPH。
- 症状和功能障碍严重程度在病因或治疗并发症导致额外神经损伤或存在多种合并症时更重。
- 超过半数过渡期、未识别先天性和获得性脑积水患者仅有轻微或无功能障碍。
研究设计与样本
- 前瞻性注册研究,非连续入组6个中心的≥18岁成人患者。
- 共纳入517例患者,年龄范围18.1至90.7岁。
- 所有患者接受标准化评估,包括蒙特利尔认知评估、符号数字模态测试、贝克抑郁量表II等。
主要发现
- 各组比例:过渡期16.6%,未识别先天性26.5%,获得性18.2%,疑似iNPH 38.7%。
- 过渡期组平均年龄32.7±10.0岁最年轻,疑似iNPH组76.5±5.2岁最年长。
- 排除86例过渡期患者(均已治疗),其余3组中79.4%在入组时未治疗。
- 疑似iNPH组认知评估表现最差,未识别先天性组表现最佳;Lawton ADL/IADL评分呈相同模式。
- 疑似iNPH组步速最低;合并症最多或病因直接导致神经损伤的类别(过渡期、获得性)功能障碍程度更重。
临床怎么用
- 成人脑积水评估应涵盖过渡期、未识别先天性和获得性等非iNPH类别,避免仅关注iNPH。
- 对未治疗的无症状或轻微症状的未识别先天性和获得性脑积水患者,需进一步研究确定治疗必要性。
- 疑似iNPH患者中需进一步诊断测试以识别真正可能从治疗中获益的脑积水患者。
局限性
- 患者为非连续入组,可能存在选择偏倚。
- 疑似iNPH组年龄≥65岁且未经治疗,诊断标准基于临床怀疑而非确诊。
- 未报告各评估工具的具体数值和统计比较结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors describe the demographics and clinical characteristics of the first 517 patients enrolled in the Adult Hydrocephalus Clinical Research Network (AHCRN) during its first 2 years. METHODS: Adults ≥ 18 years were nonconsecutively enrolled in a registry at 6 centers. Four categories of adult hydrocephalus were defined: transition (treated before age 18 years), unrecognized congenital (congenital pattern, not treated before age 18 years), acquired (secondary to known risk factors, treated or untreated), and suspected idiopathic normal pressure hydrocephalus (iNPH) (≥ age 65 years, not previously treated). Data include etiology, symptoms, examination findings, neuropsychology screening, comorbidities, treatment, complications, and outcomes. Standard evaluations were administered to all patients by trained examiners, including the Montreal Cognitive Assessment, the Symbol Digit Modalities Test, the Beck Depression Inventory-II, the Overactive Bladder Questionnaire Short Form symptom bother, the 10-Meter Walk Test, the Boon iNPH gait scale, the Lawton Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) questionnaire, the iNPH grading scale, and the modified Rankin Scale. RESULTS: Overall, 517 individuals were enrolled. Age ranged from 18.1 to 90.7 years, with patients in the transition group (32.7 ± 10.0 years) being the youngest and those in the suspected iNPH group (76.5 ± 5.2 years) being the oldest. The proportion of patients in each group was as follows: 16.6% transition, 26.5% unrecognized congenital, 18.2% acquired, and 38.7% suspected iNPH. Excluding the 86 patients in the transition group, who all had received treatment, 79.4% of adults in the remaining 3 groups had not been treated at the time of enrollment. Patients in the suspected iNPH group had the poorest performance in cognitive evaluations, and those in the unrecognized congenital group had the best performance. The same pattern was seen in the Lawton ADL/IADL scores. Gait velocity was lowest in patients in the suspected iNPH group. Categories that had the most comorbidities (suspected iNPH) or etiologies of hydrocephalus that directly cause neurological injury (transition, acquired) had greater degrees of impairment compared to unrecognized congenital, which had the fewest comorbidities or etiologies associated with neurological injury. CONCLUSIONS: The clinical spectrum of hydrocephalus in adults comprises more than iNPH or acquired hydrocephalus. Only 39% of patients had suspected iNPH, whereas 43% had childhood onset (i.e., those in the transition and unrecognized congenital groups). The severity of symptoms and impairment was worsened when the etiology of the hydrocephalus or complications of treatment caused additional neurological injury or when multiple comorbidities were present. However, more than half of patients in the transition, unrecognized congenital, and acquired hydrocephalus groups had minimal or no impairment. Excluding the transition group, nearly 80% of patients in the AHCRN registry were untreated at the time of enrollment. A future goal for the AHCRN is to determine whether patients with unrecognized congenital and acquired hydrocephalus need treatment and which patients in the suspected iNPH cohort actually have possible hydrocephalus and should undergo further diagnostic testing. Future prospective research is needed in the diagnosis, treatment, outcomes, quality of life, and macroeconomics of all categories of adult hydrocephalus.
引用
- Williams MA, Nagel SJ, Luciano MG, et al. The clinical spectrum of hydrocephalus in adults: report of the first 517 patients of the Adult Hydrocephalus Clinical Research Network registry. J Neurosurg. 2019. PMID: 31125971. doi:10.3171/2019.2.JNS183538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。